Our insight of the sepsis response has evolved to encompass not only the pro-inflammatory but also an anti-inflammatory reaction following infection. Clinical trials have been designed to target either bacterial products, endotoxin in particular, or mediators involved in the sepsis response, but until recently the majority of them have given unfavorable results. In this article, we provide a scope of clinical trials that have been done in immunomodulation during sepsis whether or not they provide positive results. We will also discuss some of the reasons why those studies have been disappointing. Current and future trials with a better assessment of inflammatory status of patients and better-defined outcomes such as organ dysfunction are now underway.
References
1.
Suffredini AF , Fromm RE, Parker MM et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med1989; 321: 280—287.
2.
Schedel I., Dreikhausen U., Nentwig B.Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med1991; 19: 1104—1113.
3.
Ziegler EJ, McCutchan JA, Fierer J. et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med1982; 307: 1225—1230.
4.
Calandra T., Glauser MP, Schellekens J., Verhoef J.Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis1988; 158: 312—319.
5.
Angus D., Birmingham MC, Balk R. et al. E5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis. A randomized controlled trial. JAMA2000; 283: 1723—1730.
6.
Ziegler EJ, Fisher CJ, Sprung CL et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med1991; 324: 429—436.
7.
McCloskey RV , Straube RC, Sanders C. et al. CHESS Trial Study Group. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind placebo-controlled trial. Ann Intern Med1994 ; 121: 1—5.
8.
Derkx B., Wittes J., McCloskey R.Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis1999; 28: 770—777.
9.
The National Committee for the Evaluation of Centoxin.The French national registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. Arch Intern Med1994; 154: 2484—2491.
10.
Elsbach P., Weiss J.Role of the bactericidal/permeability-increasing protein in host defence . Curr Opin Immunol1998; 10: 45—49.
11.
Giroir BP, Quint PA, Barton P. et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet1997; 350: 1439—1443.
12.
Iwana H., Komatsu T.Effect of an endotoxin-removing column containing immobilized polymyxin B fiber in a patient with septic shock from Gram-positive infection. Acta Anaesthesiol Scand1998; 42: 590—-593.
13.
Tabardel Y. , Duchateau J., Schmartz D. et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men . Surgery1996; 119: 76—80
14.
Bone RC, Fisher CJ, Clemmer TP et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med1987; 317: 653—658.
15.
The Veterans Administration Systemic Sepsis Cooperative Study Group.Effect of high-dose glucocorticosteroid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl Med1987; 317: 659—665.
16.
Lefering R. , Neugebauer EASteroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med1995; 23: 1294—1303.
17.
Cronin L., Cook DJ, Carlet J. et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med1995; 23: 1430—1439.
18.
Bollaert PE , Charpentier C., Levy B. et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med1998; 26: 645—650.
19.
Briegel J.Forst H.Haller M. et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med1999; 27: 723—732.
20.
Abraham E., Wunderink R., Silverman H. et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA1995; 273: 934—941.
21.
Cohen J., Carlet J.INTERSEPT Study Group. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med1996; 24: 1431—1440.
22.
Abraham E., Anzueto A., Gutierrez G. et al. Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. Lancet1998; 351: 929—933.
23.
Reinhart K. , Wiegand-Lohnert C., Grimminger F. et al. Assessment of the safety and efficacy of the monoclonal antitumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med1996; 24: 733—742.
24.
Casey LC, Balk RA, Bone RCPlasma cytokines and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Intern Med1993; 119: 771—778.
25.
Reinhart K.RAMSES Study Group.Treatment of severe sepsis in patients with highly elevated IL-6 levels with anti-TNF monoclonal antibody MAK 195F: The RAMSES study. Crit Care Med1998; 2: P18.
26.
Dinarello CAProinflammatory and antiinflammatory cytokines as mediators in the pathogenesis of septic shock. Chest1997; 112: S321—S329.
27.
Fisher CJ, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med1996; 334: 1697—1702.
28.
Abraham E., Glauser MP, Butler T. et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA1997; 277: 1531—1538.
29.
Arend WP, Malyak M., Guthridge CJ, Gabay C.Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol1998; 16: 27—55.
30.
Fisher CJ, Dhainaut JF, Opal SM et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA1994 ; 271: 1836—1843.
31.
Opal SM, Fisher CJ, Dhainaut JF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double blind, placebo-controlled, multicenter trial. Crit Care Med1997; 25: 1115—1124.
32.
Fein AM, Bernard GR, Criner GJ et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). JAMA1997; 277: 482—487.
33.
Fourrier F. , Jourdain M., Tournois A. et al. Coagulation inhibitor substitution during sepsis. Intensive Care Med1995; 21: S264—S268.
34.
Baudo F., Caimi TM, deCataldo F. et al. Antithrombin III (AT III) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled, double-blind, randomized, multicenter study. Intensive Care Med1998 ; 24: 336—342.
35.
Wort SJ, Evans TWThe role of the endothelium in modulating vascular control in sepsis and related conditions. Br Med Bull1999; 55: 30—48.
36.
Friedman G. , Jankowski S., Shahla M. et al. Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med1996; 24: 229—233.
37.
Dhainaut JF , Tenaillon A., Le Tulzo Y. et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group . Crit Care Med1994; 22: 1720—1728.
38.
Dhainaut JF , Tenaillon A., Hemmer M. et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Study Group. Crit Care Med1998; 26: 1963—1971.
39.
Vincent JL, Spapen H., Bakker J. et al. Phase II multicenter clinical study of the platelet activating factor BB-882 in the treatment of sepsis. Crit Care Med2000: 28: 638—642.
40.
Bulger EM, Maier RVLipid mediators in the pathophysiology of critical care illness. Crit Care Med2000; 28: N27—N36.
41.
Vincent JL, Brase R., Dhainaut JF et al. A multicenter, double blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome [abstract]. Crit Care Med1999; 27: A164.
42.
Bernard GR, Wheeler AP, Russell JA et al. The effects of ibuprofen on physiology and survival of patients with sepsis. N Engl J Med1997; 336: 912—918.
43.
The ARDS Network Authors for the ARDS Network.Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome. A randomized controlled trial. JAMA2000; 283: 1995—2002.
44.
Gutteridge Jmc, Mitchell J.Redox imbalance in the critically ill. Br Med Bull1999; 55: 49—75.
45.
Spapen H., Zhang H., Demanet C. et al. Does N-acetyl-L-cysteine influence cytokine response during early septic shock?Chest1998; 113: 1616—1624.
46.
Quilan GJ, Margarson M., Mumby S. et al. Administration of albumin to patients with sepsis syndrome: a possible role in plasma thiol repletion. Clin Sci1998; 95: 459—465.
47.
Symeonides S. , Balk RANitric oxide in the pathogenesis of sepsis . Infect Dis Clin North Am1999; 13: 449—463.
48.
Grover R., Lopez A., Lorente J. et al. Multicenter, randomized, placebo-controlled, double blind study of nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock [abstract]. Crit Care Med1999; 27: A33.
49.
Rogiers P., Zhang H., Vincent JLHemofiltration in sepsis and septic shock. In: Vincent JL. (ed) Yearbook of Intensive Care and Emergency Medicine. Heidelberg: Springer, 1997; 133—139.
50.
Cheadle WG, Hanasawa K., Gallinaro RN et al. Endotoxin filtration and immune stimulation improve survival from Gram-negative sepsis. Surgery1991; 110: 785—792.
51.
Ronco C., Bellomo R., Homel P. et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000; 356: 26—30.
52.
Wasserman D. , Ioannovich JD, Hinzmann RD et al. Interferon-γ in the prevention of severe burn-related infections: a European phase III multicenter trial . Crit Care Med1998; 26: 434—439.
53.
Döcke WD, Randow F., Syrbe U. et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med1997; 3: 678—681.
54.
Esposito C. , Banks SM, Eichacker PQProphylactic granulocyte colony-stimulating factor in critically ill patients: not time yet. Crit Care Med1998; 26: 636.
55.
Mahidharar R., Billiar TRApoptosis in sepsis. Crit Care Med2000; 28: N105—N113.
56.
Bone RCWhy sepsis trials fail. JAMA1996; 276: 565—566.
57.
Vincent JLSearch for effective immunomodulating strategies against sepsis. Lancet1998; 351: 922—923.
58.
American College of Chest Physicians/Society of Critical Care Medicine.Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med1992; 20: 864—874.
59.
Petros AJ, Marshall JC, van Saene HK.Should morbidity replace mortality as en endpoint for clinical trials in intensive care?Lancet1995; 345: 369—371.
60.
Vincent JL, de Mendonça A., Cantraine F. et al. Use of the SOFA score to assess the incidence of organ dysfunction score/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med1998; 26: 1793—1800.
